Gout Dose Response Study
5 février 2014 mis à jour par: Ardea Biosciences, Inc.
Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout
To compare the proportion of subjects whose serum urate (sUA) level is < 6.0 mg/dL after 28 days of dosing by treatment group.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
123
Phase
- Phase 2
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Goch, Allemagne, 47574
-
Hamburg, Allemagne, 22143
-
Nuremberg, Allemagne, 90402
-
-
-
-
-
Pleven, Bulgarie, 5800
-
Plovdiv, Bulgarie, 4002
-
Plovidv, Bulgarie, 4002
-
Sofia, Bulgarie, 1233
-
Sofia, Bulgarie, 1709
-
Varna, Bulgarie, 9010
-
-
-
-
British Columbia
-
Coquitlam, British Columbia, Canada, V3K 3P4
-
Kelowna, British Columbia, Canada, V1Y8E7
-
-
Ontario
-
Thornhill, Ontario, Canada, L4J6W6
-
Toronto, Ontario, Canada, M9W 4L6
-
-
Quebec
-
Mirabel, Quebec, Canada, J7J 2K8
-
-
-
-
-
Tbilisi, Géorgie, 0186
-
Tbilisi, Géorgie, 0102
-
-
-
-
-
Elblag, Pologne, 82-300
-
Lodz, Pologne, 90-153
-
Lublin, Pologne, 20-607
-
Poznan, Pologne, 61-289
-
Radom, Pologne, 26-610
-
Wroclaw, Pologne, 53-025
-
-
-
-
-
Bruntal, République tchèque, 792 01
-
Prague, République tchèque, 140 00
-
Prague, République tchèque, 148 00
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90017
-
-
Florida
-
DeLand, Florida, États-Unis, 32720
-
-
North Carolina
-
Winston-Salem, North Carolina, États-Unis, 27103
-
-
Tennessee
-
Jackson, Tennessee, États-Unis, 38305
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 75 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Male or post-menopausal or surgically sterile female.
- 18 - 75 years of age.
- Hyperuricemic (i.e., screening sUA ≥8 mg/dL).
- Meets criteria for the diagnosis of gout as per the American Rheumatism Association (ARA) Criteria for the Classification of Acute Arthritis of Primary Gout.
- Willing and able to give informed consent and adhere to visit/protocol schedules (informed consent must be given before the first study procedure is performed).
- Subjects entering the optional Extension Period must have successfully completed the Double-Blind Treatment Period and Follow-up Period within approximately 4 months and must not have experienced any serious adverse events considered possibly related to study drug.
Exclusion Criteria:
- Classified as an overproducer of urine urate (Cur > 6.0 ml/min/1.73 m2 24- hour urine).
- Consumes more than 14 drinks of alcohol per week (e.g., 1 drink = 5 oz [150 ml] of wine, 12 oz [360 ml] of beer, or 1.5 oz [45 ml] of hard liquor).
- History or suspicion of drug abuse.
- Documented history of or suspicion of kidney stones.
- History of rheumatoid arthritis or other autoimmune disease.
- Confirmed (positive serology to HIV1 and HIV 2) or suspected HIV infection.
- Positive serology to HCV antibodies (Abs), and/or hepatitis B surface antigen (HBsAg).
- History of malignancy, except treated non-melanomatous skin cancer or cervical dysplasia.
- History of cardiac abnormalities, including abnormal and clinically relevant ECG changes such as bradycardia (sinus rate <45 bpm), complete left bundle branch block (LBBB), second or third degree heart block, intraventricular conduction delay with QRS duration >120 msec, symptomatic or asymptomatic arrhythmias with the exception of sinus arrhythmia, evidence of ventricular pre-excitation, frequent palpitations or syncopal episodes, heart failure, hypokalemia, family history of Long QT Syndrome, and/or family history of sudden death in an otherwise healthy individual between the ages of 1 and 30 years.
- Any condition predisposing them to QT prolongation including pathological Q-wave (defined as Q-wave >40 msec or depth > 0.4-0.5 mV).
- Any use of a concomitant medication that prolong the QT/QTc interval within the 14 days prior to Baseline (Day 0)
- QT interval corrected for heart rate according to Fridericia (QTcF) > 450 msec at Screening or pre-dose at Baseline (Day 0)
- Uncontrolled hypertension (above 150/95)
- Inadequate renal function
- Hemoglobin < 10 g/dL (males) or < 9 g/dL (females)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x upper limit of normal (ULN)
- Gamma glutamyl transferase (GGT) > 3 x ULN
- Active peptic ulcer disease requiring treatment
- History of xanthinuria, active liver disease, or hepatic dysfunction.
- Requires therapy with any other urate-lowering medication, other than the study medication.
- Requires long-term use of salicylates; diuretics; azathioprine; mercaptopurine; theophylline; intravenous colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole; or trimethoprim
- Taking medications known as enzyme inducers
- Receiving a strong or moderate inhibitor of CYP3A4 or a P-gp inhibitor within 1 month prior to study drug dosing
- Gout flare at screening that is resolved for less than one week prior to the first treatment with study medication (exclusive of chronic synovitis/ arthritis)
- Female of childbearing potential
- Received an investigational medication within 4 weeks prior to study medication administration
- Previously participated in a clinical study involving RDEA806 or RDEA594.
- Known hypersensitivity or allergy to RDEA594 or colchicine or any components in their formulations.
- Body mass index (BMI) >40 kg/m2.
- Taking greater than 1000 mg/day of Vitamin C.
- Any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
- Inadequate renal function after completing the Double-Blind Treatment period prior to entering Extension Period.
- Requiring treatment with prohibited medications noted in exclusion criteria numbers 20-23 after completing the Double-Blind Treatment Period prior to entering the Extension Period.
- Clinically relevant medical event as determined by the investigator in consultation with medical monitor prior to entering the Extension Period.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: RDEA594 200 mg qd for 28 days
|
Uricosuric agent for the treatment of gout
|
|
Expérimental: RDEA594 200 mg, 400 mg
RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days
|
Uricosuric agent for the treatment of gout
|
|
Expérimental: RDEA594 200 mg, 400 mg and 600 mg
RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days
|
Uricosuric agent for the treatment of gout
|
|
Comparateur placebo: Matching placebo
RDEA594 matching placebo qd for 28 days
|
Placebo correspondant
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
To compare the proportion of subjects whose serum urate (sUA) level is < 6.0 mg/dL after 28 days of dosing by treatment group.
Délai: 28 Days
|
28 Days
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
To evaluate the proportion of subjects whose sUA levels are <6.0 mg/dL, <5.0 mg/dL and <4.0 mg/dL at each weekly study visit during the Double-Blind Period.
Délai: 28 Days
|
28 Days
|
|
To evaluate the absolute and percent reduction from baseline in sUA levels at each weekly study visit.
Délai: 28 Days and through extension
|
28 Days and through extension
|
|
To evaluate the percentage change in 24-hour urine urate level (excretion) from baseline to Day 28.
Délai: 28 Days and through extension
|
28 Days and through extension
|
|
To evaluate the incidence of gout flares.
Délai: 28 Days and through extension
|
28 Days and through extension
|
|
To evaluate the safety and tolerability of RDEA594 in subjects with gout.
Délai: 28 Days and through extension
|
28 Days and through extension
|
|
To evaluate the proportion of subjects whose sUA level decreases to or is maintained at <6.0 mg/dL in the Open-Label Extension Period.
Délai: 18 Months
|
18 Months
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Directeur d'études: Vijay Hingorani, MD, PhD, MBA, Ardea Biosciences, Inc.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 juillet 2009
Achèvement primaire (Réel)
1 mars 2010
Achèvement de l'étude (Réel)
1 septembre 2011
Dates d'inscription aux études
Première soumission
7 août 2009
Première soumission répondant aux critères de contrôle qualité
7 août 2009
Première publication (Estimation)
10 août 2009
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
7 mars 2014
Dernière mise à jour soumise répondant aux critères de contrôle qualité
5 février 2014
Dernière vérification
1 février 2014
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- RDEA594-202
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .